首页> 外文期刊>Rheumatology international. >Reevaluation of predictive value of ACL and anti-β2GP1 antibody for thrombosis in patients with systemic lupus erythematosus: From a perspective of a practical world
【24h】

Reevaluation of predictive value of ACL and anti-β2GP1 antibody for thrombosis in patients with systemic lupus erythematosus: From a perspective of a practical world

机译:从实用世界的角度重新评估ACL和抗β2GP1抗体对系统性红斑狼疮患者血栓形成的预测价值

获取原文
获取原文并翻译 | 示例
           

摘要

Detection of ACL (anticardiolipin, ACL) and anti-β2GP1 (beta2 glycoprotein1, β2GP1) antibody has been widely used, and the criteria of APS (Antiphospholipid syndrome, APS) have been used for the prediction of thrombosis in patients with SLE. What is the exact predictive value of these two antibodies? Is it really necessary to apply the criteria of APS to each patient just for the purpose of prediction of thrombosis? The aim of this retrospective study is to reevaluate the predictive value of diVerent combination of ACL and anti-β2GP1 antibody for thrombosis formation in Chinese patients with SLE. Patients fulWlling the 1997 ACR classification criteria for SLE were enrolled and retrospectively analyzed. Thrombosis was conWrmed by ultrasound, cerebral MRI, computed tomography pulmonary angiogram and angiography. Both IgG and IgM isotype of ACL and anti-β2GP1 antibody were detected with ELISA kit. ROC curves and other parameters of diagnostic test for diVerent combination of ACL and anti- β2GP1 were analyzed and compared. 175 patients were recruited and thrombosis was diagnosed in 49 patients. In patients with thrombosis, 95.9% had been treated with glucocorticoids before detection of the two antibodies, 44.9% had hypertension and 53.1% had hyperlipidemia. ACL was positive in 28 patients (16%), and anti-β2GP1 antibody was positive in 21 patients (12%). The presence of a low or higher titer of either ACL (>12 RU/ml) or anti-β2GP1 antibody (>20 RU/ml) once has the highest predictive accuracy. The sensitivity, the specificity, the Youden's index and the area under ROC curve are 61.11%, 81.11%, 0.4222 and 0.711 respectively. A transient low or higher titer of ACL or anti-β2GP1 antibody had a good predictive value for thrombosis in patients with SLE, especially in those with other traditional risk factors for thrombosis and those treated with glucocorticoids.
机译:ACL(抗心磷脂,ACL)和抗β2GP1(β2糖蛋白1,β2GP1)抗体的检测已被广泛使用,APS(抗磷脂综合征,APS)的标准已被用于预测SLE患者的血栓形成。这两种抗体的确切预测价值是什么?真的有必要仅仅为了预测血栓形成而对每位患者应用APS标准吗?这项回顾性研究的目的是重新评估ACL和抗β2GP1抗体的不同组合对中国SLE患者血栓形成的预测价值。符合1997年ACR SLE分类标准的患者入选并进行回顾性分析。通过超声,脑MRI,计算机断层扫描肺血管造影和血管造影证实血栓形成。用ELISA试剂盒检测ACL的IgG和IgM同种型以及抗β2GP1抗体。分析并比较了ACL和抗β2GP1的不同组合的ROC曲线和诊断测试的其他参数。招募了175例患者,其中49例被诊断出血栓形成。在有血栓形成的患者中,在检测到两种抗体之前,接受糖皮质激素治疗的比例为95.9%,其中高血压的比例为44.9%,高脂血症的比例为53.1%。 ACL阳性28例(16%),抗β2GP1抗体阳性21例(12%)。 ACL(> 12 RU / ml)或抗β2GP1抗体(> 20 RU / ml)滴度较低或较高的预测准确性最高。灵敏度,特异度,尤登指数和ROC曲线下面积分别为61.11%,81.11%,0.4222和0.711。短暂的较低或较高滴度的ACL或抗β2GP1抗体对SLE患者的血栓形成具有良好的预测价值,尤其是在那些具有其他传统血栓危险因素的患者和接受糖皮质激素治疗的患者中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号